Ketamine disrupts abnormal brain activity, offering long-term relief for Parkinson’s dyskinesia in early clinical trials.

The US company has said it is launching the Phase III trials in the first half of this year after Phase I talks with the US ...

Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...

Medtronic is the originator of continuous deep brain stimulation (cDBS), which has been available for decades as a proven ...

Berlin, Germany, and Research Triangle Park, N.C., USA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Not intended for UK MediaEnrollment ongoing in the ...

Medtronic’s BrainSense aDBS is a therapy intended to improve the quality of life for individuals living with Parkinson’s ...

While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now ...

Medtronic (NYSE: MDT) announced today that it received CE mark approval for its BrainSense adaptive deep brain stimulation ...

Mytos’ technology will automate the manufacturing of neuronal precursors for Aspen's autologous cell therapy for the brain disorder.

Aspen Neuroscience, Inc. has successfully completed dose escalation and the first two cohorts of patients in the ASPIRO study, an ANPD001 Phase 1/2a clinical trial in Parkinson's Disease (PD).